92 related articles for article (PubMed ID: 9812363)
1. Efficacy of select antivirals against Cryptosporidium parvum in vitro.
Woods KM; Upton SJ
FEMS Microbiol Lett; 1998 Nov; 168(1):59-63. PubMed ID: 9812363
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of 101 antimicrobials and other agents on the development of Cryptosporidium parvum in vitro.
Woods KM; Nesterenko MV; Upton SJ
Ann Trop Med Parasitol; 1996 Dec; 90(6):603-15. PubMed ID: 9039272
[TBL] [Abstract][Full Text] [Related]
3. [Highly Active AntiRetroviral Therapy and cryptosporidiosis].
Morales Gomez MA
Parassitologia; 2004 Jun; 46(1-2):95-9. PubMed ID: 15305695
[TBL] [Abstract][Full Text] [Related]
4. Development of a microtitre ELISA to quantify development of Cryptosporidium parvum in vitro.
Woods KM; Nesterenko MV; Upton SJ
FEMS Microbiol Lett; 1995 Apr; 128(1):89-94. PubMed ID: 7744242
[TBL] [Abstract][Full Text] [Related]
5. Effect of Ginsenoside-Rh2 and Curcurbitacin-B on Cryptosporidium parvum in vitro.
Shahiduzzaman M; Ras R; Widmer G
Exp Parasitol; 2020 May; 212():107873. PubMed ID: 32165146
[TBL] [Abstract][Full Text] [Related]
6. Activity of decoquinate against Cryptosporidium parvum in cell cultures and neonatal mice.
Lindsay DS; Woods KM; Upton SJ; Blagburn BL
Vet Parasitol; 2000 May; 89(4):307-11. PubMed ID: 10799844
[TBL] [Abstract][Full Text] [Related]
7. Combination of cell culture and quantitative PCR for screening of drugs against Cryptosporidium parvum.
Shahiduzzaman M; Dyachenko V; Obwaller A; Unglaube S; Daugschies A
Vet Parasitol; 2009 Jun; 162(3-4):271-7. PubMed ID: 19342176
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of cryptosporidium parvum in vitro by 9-(alkylthio)acridine derivatives.
Khalifa L; Rosales MJ; Mascaro C; Karolak-Wojciechowska J; Bsiri N; Brouant P; Barbe J
Arzneimittelforschung; 2000 Feb; 50(2):163-6. PubMed ID: 10719621
[TBL] [Abstract][Full Text] [Related]
9. The development of a real-time quantitative-PCR method for characterisation of a Cryptosporidium parvum in vitro culturing system and assessment of drug efficacy.
MacDonald LM; Sargent K; Armson A; Thompson RC; Reynoldson JA
Mol Biochem Parasitol; 2002 May; 121(2):279-82. PubMed ID: 12034463
[No Abstract] [Full Text] [Related]
10. Inhibitory activities of epidermal growth factor receptor tyrosine kinase-targeted dihydroxyisoflavone and trihydroxydeoxybenzoin derivatives on Sarcocystis neurona, Neospora caninum, and Cryptosporidium parvum development.
Gargala G; Baishanbo A; Favennec L; François A; Ballet JJ; Rossignol JF
Antimicrob Agents Chemother; 2005 Nov; 49(11):4628-34. PubMed ID: 16251305
[TBL] [Abstract][Full Text] [Related]
11. In vitro assays of maduramicin activity against Cryptosporidium parvum.
Arrowood MJ; Xie LT; Hurd MR
J Eukaryot Microbiol; 1994; 41(5):23S. PubMed ID: 7804225
[No Abstract] [Full Text] [Related]
12. Hemolytic properties of lytic peptides active against the sporozoites of Cryptosporidium parvum.
Arrowood MJ; Jaynes JM; Healey MC
J Protozool; 1991; 38(6):161S-163S. PubMed ID: 1818150
[TBL] [Abstract][Full Text] [Related]
13. Treatment with agmatine inhibits Cryptosporidium parvum infection in infant mice.
Moore D; Waters WR; Wannemuehler MJ; Harp JA
J Parasitol; 2001 Feb; 87(1):211-3. PubMed ID: 11227893
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of chitosan, a natural polysaccharide, against Cryptosporidium parvum in vitro and in vivo in neonatal mice.
Mammeri M; Chevillot A; Thomas M; Polack B; Julien C; Marden JP; Auclair E; Vallée I; Adjou KT
Exp Parasitol; 2018 Nov; 194():1-8. PubMed ID: 30237052
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Calcium-Dependent Protein Kinase 1 (CDPK1) In Vitro by Pyrazolopyrimidine Derivatives Does Not Correlate with Sensitivity of Cryptosporidium parvum Growth in Cell Culture.
Kuhlenschmidt TB; Rutaganira FU; Long S; Tang K; Shokat KM; Kuhlenschmidt MS; Sibley LD
Antimicrob Agents Chemother; 2016 Jan; 60(1):570-9. PubMed ID: 26552986
[TBL] [Abstract][Full Text] [Related]
16. Immunofluorescence detection of Cryptosporidium parvum in Caco-2 cells: a new screening method for anticryptosporidial agents.
Favennec L; Egraz-Bernard M; Comby E; Lemeteil D; Ballet JJ; Brasseur P
J Eukaryot Microbiol; 1994; 41(5):39S. PubMed ID: 7804239
[No Abstract] [Full Text] [Related]
17. Effects of manganese salts on the AIDS-related pathogen, Cryptosporidium parvum in vitro and in vivo.
Nesterenko MV; Woods KM; Upton SJ
Biol Trace Elem Res; 1997 Mar; 56(3):243-53. PubMed ID: 9197922
[TBL] [Abstract][Full Text] [Related]
18. Improved efficacy of dinitroaniline analogs for use as anti-cryptosporidial drugs.
Mead JR; Benbow JW; Garmon D; Stewart J
J Eukaryot Microbiol; 1999; 46(5):62S-63S. PubMed ID: 10519250
[No Abstract] [Full Text] [Related]
19. Unexpected activity of beta-cyclodextrin against experimental infection by Cryptosporidium parvum.
Castro-Hermida JA; Freire-Santos F; Oteiza-Löpez AM; Ares-Mazás E
J Parasitol; 2000 Oct; 86(5):1118-20. PubMed ID: 11128490
[TBL] [Abstract][Full Text] [Related]
20. Paromomycin and geneticin inhibit intracellular Cryptosporidium parvum without trafficking through the host cell cytoplasm: implications for drug delivery.
Griffiths JK; Balakrishnan R; Widmer G; Tzipori S
Infect Immun; 1998 Aug; 66(8):3874-83. PubMed ID: 9673275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
